gemfibrozil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
1285 25812-30-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • gemfibrosil
  • gemfibrozil
  • decrelip
  • lopizid
A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.
  • Molecular weight: 250.34
  • Formula: C15H22O3
  • CLOGP: 3.94
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 46.53
  • ALOGS: -3.95
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.02 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 79.89 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 98 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EGFR,EIF2AK3,ERBB2,GRK2,IKBKB,ITK,MAP2K6,MAPK14,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PRKDC,TEK,TGFBR1,ZAP70 30
kinase-selectivity-class AXL,BRAF,ERBB2,GRK2 4
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1

Approvals:

DateAgencyCompanyOrphan
Dec. 21, 1981 FDA PFIZER PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rhabdomyolysis 259.73 14.53 126 10892 51130 90566299
Blood triglycerides increased 70.12 14.53 34 10984 13727 90603702
Coronary artery disease 69.52 14.53 46 10972 33577 90583852
Myocardial infarction 68.42 14.53 74 10944 105898 90511531
Drug hypersensitivity 61.70 14.53 158 10860 463451 90153978
Blood creatine phosphokinase increased 57.24 14.53 41 10977 33982 90583447
Cardiac failure congestive 51.94 14.53 62 10956 98632 90518797
Drug interaction 48.45 14.53 105 10913 276348 90341081
Myalgia 47.35 14.53 80 10938 175045 90442384
Cerebrovascular accident 46.84 14.53 66 10952 123467 90493962
Acute interstitial pneumonitis 45.61 14.53 12 11006 807 90616622
Off label use 37.06 14.53 48 10970 1102204 89515225
Pancreatitis 36.95 14.53 44 10974 69782 90547647
Myopathy 36.74 14.53 22 10996 13496 90603933
Lip infection 35.20 14.53 7 11011 132 90617297
Pancreatitis acute 35.11 14.53 30 10988 32085 90585344
Blood glucose increased 34.79 14.53 50 10968 95196 90522233
Diabetes mellitus 32.88 14.53 40 10978 64835 90552594
Synovitis 29.37 14.53 3 11015 329749 90287680
Treatment failure 26.47 14.53 3 11015 303925 90313504
Renal failure 25.51 14.53 52 10966 130955 90486474
Tendon rupture 25.00 14.53 15 11003 9228 90608201
Infusion related reaction 24.52 14.53 10 11008 416770 90200659
Completed suicide 24.13 14.53 54 10964 145004 90472425
Wound 24.00 14.53 4 11014 302976 90314453
Drug intolerance 22.88 14.53 13 11005 447578 90169851
Arthropathy 22.85 14.53 8 11010 366234 90251195
Chronic kidney disease 22.33 14.53 29 10989 50162 90567267
Urinary tract infection 20.96 14.53 83 10935 305549 90311880
Microalbuminuria 20.89 14.53 6 11012 559 90616870
Joint swelling 20.05 14.53 19 10999 503281 90114148
Bronchitis viral 20.05 14.53 7 11011 1228 90616201
Infected bite 19.83 14.53 8 11010 2089 90615340
Diabetes mellitus inadequate control 19.50 14.53 17 11001 18667 90598762
Osteomyelitis acute 19.46 14.53 5 11013 306 90617123
Transient ischaemic attack 19.29 14.53 25 10993 43151 90574278
Hypertriglyceridaemia 19.29 14.53 12 11006 7877 90609552
Blood urea increased 19.19 14.53 21 10997 30392 90587037
Hypoglycaemia 18.97 14.53 32 10986 69816 90547613
Cardio-respiratory arrest 18.59 14.53 30 10988 63110 90554319
Hyperlipidaemia 18.38 14.53 18 11000 22898 90594531
Periodontitis 18.07 14.53 9 11009 3844 90613585
Hypophagia 17.95 14.53 22 10996 35915 90581514
Acute kidney injury 17.34 14.53 81 10937 320306 90297123
Hepatic enzyme increased 16.35 14.53 12 11006 360724 90256705
Blood creatine phosphokinase MB increased 16.29 14.53 6 11012 1226 90616203
Granulocytopenia 16.26 14.53 10 11008 6431 90610998
Glaucoma 16.08 14.53 16 11002 20739 90596690
International normalised ratio increased 16.05 14.53 24 10994 47292 90570137
General physical health deterioration 15.85 14.53 12 11006 355103 90262326
Angioedema 15.38 14.53 28 10990 64848 90552581
Enterobacter infection 15.05 14.53 7 11011 2576 90614853
Hyperglycaemia 14.71 14.53 24 10994 50946 90566483

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rhabdomyolysis 580.08 13.71 358 15207 77661 42528109
Blood creatine phosphokinase increased 122.25 13.71 117 15448 48221 42557549
Acute kidney injury 120.34 13.71 349 15216 366988 42238782
Myalgia 104.90 13.71 151 15414 95929 42509841
Blood triglycerides increased 102.81 13.71 67 15498 15829 42589941
Myocardial infarction 81.39 13.71 155 15410 123854 42481916
Coronary artery disease 81.07 13.71 99 15466 53621 42552149
Off label use 75.03 13.71 74 15491 638261 41967509
Cardiac failure congestive 62.40 13.71 112 15453 85490 42520280
Drug hypersensitivity 54.12 13.71 115 15450 99274 42506496
Drug interaction 52.96 13.71 215 15350 266784 42338986
Polymyositis 52.72 13.71 21 15544 1752 42604018
Pancreatitis 42.81 13.71 65 15500 43203 42562567
Drug level below therapeutic 40.87 13.71 27 15538 6518 42599252
Blood cholesterol increased 39.85 13.71 49 15516 26692 42579078
International normalised ratio increased 38.94 13.71 66 15499 48102 42557668
Drug ineffective 36.50 13.71 114 15451 630083 41975687
Myopathy 30.45 13.71 31 15534 13730 42592040
Haemodialysis 30.09 13.71 27 15538 10233 42595537
Hyperglycaemia 29.61 13.71 57 15508 45802 42559968
Blood glucose increased 27.83 13.71 74 15491 73625 42532145
Chromaturia 26.61 13.71 31 15534 15958 42589812
Granulocytopenia 25.49 13.71 21 15544 7093 42598677
Chronic kidney disease 24.91 13.71 54 15511 47187 42558583
Hypertriglyceridaemia 24.60 13.71 24 15541 10102 42595668
Type 2 diabetes mellitus 24.59 13.71 32 15533 18439 42587331
Angina unstable 23.90 13.71 25 15540 11423 42594347
Asthenia 23.45 13.71 179 15386 280614 42325156
Drug abuse 23.12 13.71 5 15560 104766 42501004
Product use in unapproved indication 21.96 13.71 21 15544 184435 42421335
Thunderclap headache 21.78 13.71 6 15559 156 42605614
Iron deficiency anaemia 21.23 13.71 25 15540 13014 42592756
Blood glucose decreased 21.09 13.71 26 15539 14193 42591577
General physical health deterioration 20.73 13.71 15 15550 151231 42454539
Myositis 20.17 13.71 26 15539 14840 42590930
Angioedema 19.55 13.71 46 15519 42431 42563339
Renal failure 19.01 13.71 103 15462 143623 42462147
Blood creatinine increased 18.94 13.71 85 15480 109918 42495852
Metabolic acidosis 18.49 13.71 51 15514 51807 42553963
Condition aggravated 18.13 13.71 43 15522 260711 42345059
COVID-19 17.95 13.71 10 15555 115938 42489832
Erosive duodenitis 17.94 13.71 10 15555 1779 42603991
Fanconi syndrome 17.91 13.71 10 15555 1784 42603986
Chest pain 17.78 13.71 99 15466 139431 42466339
Tricuspid valve incompetence 17.59 13.71 21 15544 11092 42594678
Treatment noncompliance 17.55 13.71 41 15524 37631 42568139
Supraventricular tachycardia 17.30 13.71 22 15543 12386 42593384
Muscular weakness 16.28 13.71 67 15498 83431 42522339
Lacrimation decreased 15.92 13.71 3 15562 12 42605758
Otitis externa 15.71 13.71 8 15557 1186 42604584
Hypertransaminasaemia 15.54 13.71 18 15547 9209 42596561
Coronary artery stenosis 15.43 13.71 19 15546 10360 42595410
Hypoglycaemia 14.95 13.71 52 15513 59802 42545968
Interstitial lung disease 14.94 13.71 5 15560 78457 42527313
Liver function test abnormal 14.81 13.71 35 15530 32356 42573414
Breast neoplasm 14.78 13.71 3 15562 19 42605751
Intentional product use issue 14.73 13.71 4 15561 71829 42533941
Renal tubular necrosis 14.62 13.71 25 15540 18329 42587441
Pyrexia 14.26 13.71 85 15480 393957 42211813
Product complaint 14.21 13.71 14 15551 5963 42599807
C-reactive protein increased 14.09 13.71 3 15562 63557 42542213
Paralysis 14.07 13.71 15 15550 7005 42598765
Death 13.90 13.71 108 15457 471077 42134693

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rhabdomyolysis 808.81 12.82 421 21832 119980 110447066
Blood creatine phosphokinase increased 192.81 12.82 141 22112 72936 110494110
Blood triglycerides increased 184.40 12.82 92 22161 23834 110543212
Myocardial infarction 172.96 12.82 203 22050 191880 110375166
Coronary artery disease 168.34 12.82 129 22124 71561 110495485
Acute kidney injury 166.52 12.82 383 21870 635047 109931999
Myalgia 147.77 12.82 202 22051 222179 110344867
Cardiac failure congestive 113.86 12.82 146 22107 150854 110416192
Drug interaction 105.81 12.82 278 21975 499905 110067141
Off label use 96.85 12.82 96 22157 1500089 109066957
Pancreatitis 66.66 12.82 88 22165 93445 110473601
Drug hypersensitivity 65.06 12.82 220 22033 453870 110113176
Myopathy 63.16 12.82 47 22206 24913 110542133
International normalised ratio increased 50.40 12.82 74 22179 86698 110480348
Polymyositis 49.84 12.82 21 22232 3687 110563359
Granulocytopenia 48.91 12.82 31 22222 12684 110554362
Renal failure 48.85 12.82 127 22126 226447 110340599
Blood glucose increased 46.25 12.82 90 22163 132406 110434640
Hyperglycaemia 45.75 12.82 70 22183 85020 110482026
Hypertriglyceridaemia 44.45 12.82 32 22221 16122 110550924
Drug ineffective 40.79 12.82 163 22090 1520377 109046669
Chromaturia 40.54 12.82 39 22214 29321 110537725
Blood creatinine increased 39.91 12.82 103 22150 182786 110384260
Chronic kidney disease 38.56 12.82 61 22192 76230 110490816
Drug intolerance 38.19 12.82 17 22236 406495 110160551
Hyperlipidaemia 37.48 12.82 41 22212 35807 110531239
Cerebrovascular accident 37.41 12.82 100 22153 181184 110385862
Pancreatitis acute 35.86 12.82 52 22201 60222 110506824
Infusion related reaction 35.71 12.82 16 22237 381146 110185900
Haemodialysis 35.36 12.82 29 22224 17690 110549356
General physical health deterioration 35.17 12.82 21 22232 425274 110141772
Lower respiratory tract infection 34.95 12.82 4 22249 243102 110323944
Treatment failure 34.31 12.82 7 22246 277227 110289819
Joint swelling 33.72 12.82 24 22229 442821 110124225
Hypoglycaemia 33.59 12.82 73 22180 116031 110451015
Myositis 33.25 12.82 36 22217 31080 110535966
Acute myocardial infarction 33.07 12.82 60 22193 83717 110483329
Angina unstable 33.02 12.82 27 22226 16405 110550641
Acute interstitial pneumonitis 32.93 12.82 12 22241 1434 110565612
Wound 30.99 12.82 5 22248 234432 110332614
Lip infection 30.16 12.82 7 22246 166 110566880
Angioedema 29.72 12.82 63 22190 98437 110468609
Blood glucose decreased 29.57 12.82 33 22220 29455 110537591
Treatment noncompliance 28.46 12.82 52 22201 72938 110494108
Metabolic acidosis 25.81 12.82 60 22193 99684 110467362
Intentional product use issue 25.51 12.82 9 22244 247897 110319149
Blood urea increased 25.13 12.82 42 22211 54915 110512131
Glossodynia 24.73 12.82 7 22246 221997 110345049
Cardiac disorder 24.42 12.82 50 22203 76230 110490816
Coronary artery stenosis 24.33 12.82 21 22232 13737 110553309
Hyperkalaemia 24.16 12.82 71 22182 135725 110431321
Product use issue 23.57 12.82 17 22236 311678 110255368
Acute coronary syndrome 23.41 12.82 26 22227 23086 110543960
Renal cyst 22.96 12.82 23 22230 18149 110548897
High density lipoprotein decreased 22.10 12.82 14 22239 5719 110561327
Condition aggravated 22.07 12.82 75 22178 734761 109832285
Liver function test abnormal 21.84 12.82 45 22208 68905 110498141
Rheumatoid arthritis 21.81 12.82 17 22236 299596 110267450
Arteriosclerosis coronary artery 21.65 12.82 26 22227 25092 110541954
Aspartate aminotransferase increased 21.53 12.82 76 22177 159860 110407186
Iron deficiency anaemia 21.41 12.82 29 22224 31530 110535516
Erosive duodenitis 21.23 12.82 10 22243 2281 110564765
Hypophagia 21.16 12.82 38 22215 52588 110514458
Drug abuse 20.89 12.82 5 22248 177406 110389640
C-reactive protein increased 20.63 12.82 9 22244 217910 110349136
Maternal exposure during pregnancy 20.48 12.82 13 22240 254870 110312176
Peripheral swelling 20.47 12.82 31 22222 404003 110163043
Alopecia 20.47 12.82 26 22227 364727 110202319
Liver injury 20.35 12.82 3 22250 150410 110416636
Arthropathy 20.07 12.82 17 22236 287505 110279541
Coronary artery occlusion 20.00 12.82 20 22233 15752 110551294
Chest pain 19.43 12.82 136 22117 376239 110190807
Pyrexia 19.40 12.82 104 22149 898161 109668885
Product use in unapproved indication 19.31 12.82 38 22215 447339 110119707
Blood creatine phosphokinase MB increased 18.99 12.82 10 22243 2893 110564153
Intervertebral disc displacement 18.82 12.82 6 22247 478 110566568
Alanine aminotransferase increased 18.76 12.82 80 22173 183693 110383353
Diabetes mellitus 18.68 12.82 53 22200 99328 110467718
Irritable bowel syndrome 18.62 12.82 5 22248 164210 110402836
Blindness 18.27 12.82 29 22224 36330 110530716
Product complaint 18.24 12.82 18 22235 13954 110553092
Carotid artery stenosis 18.15 12.82 15 22238 9248 110557798
Tendon rupture 18.12 12.82 18 22235 14060 110552986
Ischaemic cardiomyopathy 17.88 12.82 14 22239 7997 110559049
Completed suicide 17.83 12.82 96 22157 242285 110324761
Tricuspid valve incompetence 17.83 12.82 23 22230 23850 110543196
Musculoskeletal stiffness 17.81 12.82 18 22235 279804 110287242
Thunderclap headache 17.78 12.82 6 22247 572 110566474
Muscular weakness 17.33 12.82 97 22156 248371 110318675
Myocardial ischaemia 17.31 12.82 24 22229 26660 110540386
Fanconi syndrome 17.19 12.82 10 22243 3509 110563537
Wheezing 16.73 12.82 16 22237 255214 110311832
Diabetes mellitus inadequate control 16.71 12.82 25 22228 29750 110537296
Myoglobinuria 16.66 12.82 7 22246 1221 110565825
Muscle injury 16.52 12.82 4 22249 140803 110426243
Blister 16.42 12.82 13 22240 227363 110339683
Gastrointestinal haemorrhage 16.08 12.82 71 22182 165447 110401599
Infected bite 16.01 12.82 8 22245 2077 110564969
Mitral valve incompetence 15.95 12.82 26 22227 33303 110533743
Bronchitis viral 15.91 12.82 7 22246 1364 110565682
Erectile dysfunction 15.65 12.82 19 22234 18537 110548509
Therapeutic product effect decreased 15.23 12.82 16 22237 244300 110322746
Joint range of motion decreased 15.22 12.82 3 22250 121829 110445217
Hypersensitivity 15.21 12.82 37 22216 403961 110163085
Asthenia 15.13 12.82 208 22045 688791 109878255
Swelling 14.98 12.82 30 22223 351011 110216035
Nasopharyngitis 14.94 12.82 36 22217 394325 110172721
Lung disorder 14.71 12.82 9 22244 180038 110387008
Discomfort 14.61 12.82 13 22240 214694 110352352
Hepatic steatosis 14.45 12.82 31 22222 48800 110518246
Supraventricular tachycardia 14.42 12.82 21 22232 24401 110542645
Otitis externa 13.92 12.82 8 22245 2744 110564302
Cardiopulmonary failure 13.85 12.82 12 22241 7891 110559155
Aortic valve sclerosis 13.73 12.82 7 22246 1896 110565150
Osteomyelitis acute 13.54 12.82 5 22248 620 110566426
Haematuria 13.45 12.82 42 22211 82963 110484083
Fibromyalgia 13.34 12.82 9 22244 170900 110396146
Microalbuminuria 13.29 12.82 6 22247 1243 110565803
Haematocrit decreased 13.15 12.82 36 22217 66081 110500965
Ventricular hypertrophy 12.96 12.82 11 22242 7034 110560012
Transient ischaemic attack 12.89 12.82 35 22218 63947 110503099

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C10AB04 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
Fibrates
FDA CS M0543661 Fibric Acids
FDA MoA N0000175375 Peroxisome Proliferator-activated Receptor alpha Agonists
MeSH PA D000960 Hypolipidemic Agents
MeSH PA D000963 Antimetabolites
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D057847 Lipid Regulating Agents
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D065687 Cytochrome P-450 CYP2C8 Inhibitors
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35679 antilipemic drug
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:75835 anti-anaemic agent
FDA EPC N0000175596 Peroxisome Proliferator Receptor alpha Agonist

Related Drugs by ATC class:

C10AB Fibrates 11 drugs
aluminium clofibratebezafibratecholine fenofibrateciprofibrateclofibrateclofibrideetofibratefenofibratepemafibrateronifibratesimfibrate

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertriglyceridemia indication 302870006
Primary Prevention of Coronary Heart Disease indication
Hypoalphalipoproteinemia off-label use 190785000
Primary biliary cirrhosis contraindication 31712002 DOID:12236
Disorder of gallbladder contraindication 39621005 DOID:0060262
Acute nephropathy contraindication 58574008
Leukopenia contraindication 84828003 DOID:615
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Calculus in biliary tract contraindication 266474003
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Breastfeeding (mother) contraindication 413712001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.13 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Peroxisome proliferator-activated receptor alpha Nuclear hormone receptor AGONIST EC50 4.23 IUPHAR CHEMBL
Transthyretin Secreted Kd 7 CHEMBL
Cytochrome P450 2C8 Enzyme Ki 5.74 WOMBAT-PK
Cytochrome P450 2C9 Enzyme Ki 4.52 WOMBAT-PK
Peroxisome proliferator-activated receptor gamma Nuclear hormone receptor EC50 4.17 CHEMBL
Lipoprotein lipase Enzyme WOMBAT-PK
CDGSH iron-sulfur domain-containing protein 1 Membrane other Ki 5.14 CHEMBL
Fatty acid-binding protein, liver Cytosolic other Ki 5.73 CHEMBL

External reference:

IDSource
4018639 VUID
N0000146952 NUI
D00334 KEGG_DRUG
4018639 VANDF
C0017245 UMLSCUI
CHEBI:5296 CHEBI
4TX PDB_CHEM_ID
CHEMBL457 ChEMBL_ID
DB01241 DRUGBANK_ID
D015248 MESH_DESCRIPTOR_UI
3463 PUBCHEM_CID
3439 IUPHAR_LIGAND_ID
3899 INN_ID
Q8X02027X3 UNII
4719 RXNORM
4778 MMSL
523 MMSL
d00245 MMSL
002050 NDDF
35282000 SNOMEDCT_US
387189002 SNOMEDCT_US
Q8X02027X3 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lopid HUMAN PRESCRIPTION DRUG LABEL 1 0071-0737 TABLET, FILM COATED 600 mg ORAL NDA 18 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9130 TABLET, FILM COATED 600 mg ORAL ANDA 17 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9707 TABLET, FILM COATED 600 mg ORAL ANDA 18 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 0615-8354 TABLET, FILM COATED 600 mg ORAL ANDA 15 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 10544-569 TABLET, FILM COATED 600 mg ORAL ANDA 18 sections
Gemfibrozil Human Prescription Drug Label 1 16571-784 TABLET, FILM COATED 600 mg ORAL ANDA 15 sections
Gemfibrozil Human Prescription Drug Label 1 16714-101 TABLET 600 mg ORAL ANDA 18 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 21695-732 TABLET, FILM COATED 600 mg ORAL ANDA 17 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 24658-260 TABLET, FILM COATED 600 mg ORAL ANDA 17 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 31722-128 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 33261-146 TABLET, FILM COATED 600 mg ORAL ANDA 17 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 42806-260 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 43063-745 TABLET 600 mg ORAL ANDA 11 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 43063-921 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 43353-090 TABLET, FILM COATED 600 mg ORAL ANDA 18 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 43353-772 TABLET, FILM COATED 600 mg ORAL ANDA 21 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 43602-452 TABLET 600 mg ORAL ANDA 10 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 50090-5808 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil Human Prescription Drug Label 1 50090-6913 TABLET 600 mg ORAL ANDA 18 sections
Gemfibrozil Human Prescription Drug Label 1 50090-6939 TABLET 600 mg ORAL ANDA 18 sections
Gemfibrozil Human Prescription Drug Label 1 50090-7233 TABLET, FILM COATED 600 mg ORAL ANDA 15 sections
Gemfibrozil Human Prescription Drug Label 1 50090-7234 TABLET, FILM COATED 600 mg ORAL ANDA 15 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 50090-7809 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 50268-350 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 50268-350 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 51138-588 TABLET, FILM COATED 600 mg ORAL ANDA 18 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 51655-142 TABLET 600 mg ORAL ANDA 9 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 51655-143 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 53002-1068 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil Human Prescription Drug Label 1 53002-2068 TABLET, FILM COATED 600 mg ORAL ANDA 15 sections